Occipital Nerve Stimulation

Effective: June 1, 2019

Next Review: February 2020
Last Review: April 2019

IMPORTANT REMINDER

Medical Policies are developed to provide guidance for members and providers regarding coverage in accordance with contract terms. Benefit determinations are based in all cases on the applicable contract language. To the extent there may be any conflict between the Medical Policy and contract language, the contract language takes precedence.

PLEASE NOTE: Contracts exclude from coverage, among other things, services or procedures that are considered investigational or cosmetic. Providers may bill members for services or procedures that are considered investigational or cosmetic. Providers are encouraged to inform members before rendering such services that the members are likely to be financially responsible for the cost of these services.

DESCRIPTION

Occipital nerve stimulation (ONS) delivers a small electrical charge to the occipital nerve in an attempt to prevent migraines and other headaches in patients who have not responded to medications. The device consists of a subcutaneously implanted pulse generator (in the chest wall or abdomen) attached to extension leads that are tunneled to join electrodes placed across one or both occipital nerves at the base of the skull. Continuous or intermittent stimulation may be used.

MEDICAL POLICY CRITERIA

Occipital nerve stimulation is considered investigational for all indications, including but not limited to headaches.

NOTE: A summary of the supporting rationale for the policy criteria is at the end of the policy.

CROSS REFERENCES

1. Interferential Current Stimulation, Durable Medical Equipment, Policy No. 83.07
2. Sphenopalatine Ganglion Block for Headache and Pain, Medicine, Policy No. 160
3. Spinal Cord Stimulation, Surgery, Policy No. 45
4. Peripheral Subcutaneous Field Stimulation, Surgery, Policy No. 188
5. Implantable Peripheral Nerve Stimulation for Chronic Pain of Peripheral Nerve Origin, Surgery, Policy No. 205
BACKGROUND

Implanted peripheral nerve stimulators have been used for treatment of refractory pain for many years but only recently proposed for management of craniofacial pain. Occipital, supraorbital, and infraorbital stimulation have been reported in the literature.

There are four types of headache: vascular, muscle contraction (tension), traction, and inflammatory. Primary (not the result of another condition) chronic headache is defined as headache occurring more than 15 days of the month for at least three months. An estimated 45 million Americans experience chronic headaches. For at least half of these people, the problem is severe and sometimes disabling.

Migraine is the most common type of vascular headache. Migraine headaches are usually characterized by severe pain on one or both sides of the head, an upset stomach, and, at times, disturbed vision. One- year prevalence of migraine ranges from 6% to 15% in adult men and from 14% to 35% in adult women. Migraine headaches may last a day or more and can strike as often as several times a week or as rarely as once every few years. Drug therapy for migraine is often combined with biofeedback and relaxation training. Sumatriptan is commonly used for relief of symptoms. Drugs used to prevent migraine include methysergide maleate, propranolol hydrochloride, ergotamine tartrate; amitriptyline, valproic acid, and verapamil.

Hemicrania continua, also a vascular headache, causes moderate pain with occasional severe pain on only one side of the head. At least one of the following symptoms must also occur; conjunctival injection and/or lacrimation, nasal congestion and/or rhinorrhea, or ptosis and/or miosis. Headache occurs daily and is continuous with no pain-free periods. Hemicrania continua occurs mainly in women, and its true prevalence is not known. Indomethacin usually provides rapid relief of symptoms. Other NSAIDs, including ibuprofen, celecoxib, and naproxen, can provide some relief from symptoms. Amitriptyline and other tricyclic antidepressants are effective in some patients.

Cluster headache is a vascular headache that occurs in cyclical patterns or clusters of severe or very severe unilateral orbital or supraorbital and/or temporal pain. The headache is accompanied by at least one of the following autonomic symptoms: ptosis (drooping eyelid), conjunctival injection, lacrimation, rhinorrhea, and, less commonly, facial blushing, swelling, or sweating. Bouts of one headache every other day to 8 attacks per day may last from weeks to months, usually followed by remission periods when the headache attacks stop completely. The pattern varies from one person to another, but most people have one or two cluster periods a year. During remission, no headaches occur for months, and sometimes even years. The intense pain is caused by the dilation of blood vessels, which creates pressure on the trigeminal nerve. While this process is the immediate cause of the pain, the etiology is not fully understood. It is more common in men than in woman. One-year prevalence is estimated to be 0.5 to 1.0/1,000. Management of cluster headache consists of abortive and preventive treatment. Abortive treatments include subcutaneous injection of sumatriptan, topical anesthetics sprayed into the nasal cavity, and strong coffee. Some patients respond to rapidly inhaled pure oxygen. A variety of other pharmacologic and behavioral methods of aborting and preventing attacks have been reported with wide variation in patient response.

REGULATORY STATUS

The U.S. Food and Drug Administration (FDA) has not yet cleared any occipital nerve stimulation device for treatment of headache.
The Synergy™ IPG (implantable pulse generator) device from Medtronic received marketing clearance in 1999 for management of chronic, intractable pain of the trunk or limbs, and off-label use for headache is described in the literature.

The Genesis™ neuromodulation system (St. Jude Medical) is approved by the FDA for spinal cord stimulation and has received CE mark approval in Europe for the treatment of chronic migraines.

EVIDENCE SUMMARY

The principal outcomes associated with treatment of headache are relief of pain, return to work, and improved functional level. Relief of pain can be a subjective outcome associated with a placebo effect. Therefore, data from adequately powered, blinded, randomized controlled trials (RCT) are required to control for the placebo effect and determine whether any treatment effect provides a significant advantage.

The technology must also be evaluated in general groups of patients against existing treatments. In patients with mild to moderate symptoms, occipital nerve stimulation may be compared to other forms of conservative therapy such as topical anesthetics, rest, or non-steroidal anti-inflammatory or migraine medications.

Therefore, the focus of the evidence summary is on RCTs comparing ONS-treated patients with those in a sham treatment or standard of care group.

SYSTEMATIC REVIEW

Cadalso published a systematic review (SR) evaluating the impact occipital nerve stimulation had on healthcare outcomes, for intractable primary headache disorders.[1] The SR included four RCTs, one follow-up study, and 19 case series. The authors stated that although the RCTs showed a decrease in headache frequency and improved migraine disability assessment scores, ONS did not improve pain intensity and there was heterogeneity of outcomes. In addition, the RCTs had small sample sizes and risk of bias.

Two SRs of the literature on occipital nerve stimulation (ONS) were published in 2015. Both included RCTs and observational studies. The study by Chen et al identified five RCTs and seven case series with at least 10 patients.[2] Three of the RCTs were industry-sponsored, multicenter, parallel-group trials and two were single-center crossover trials. All five included a sham control group and one trial also included a medication management group. Risk of bias was judged to be high or unclear for all trials. Meta-analyses were performed on two outcomes. A pooled analysis of 2 studies did not find a significant difference in response rate between active and sham stimulation (risk ratio [RR], 2.07; 95% confidence interval [CI], 0.50 to 8.55; p=0.31) and a pooled analysis of three studies showed a significantly greater reduction in the number of days with prolonged moderate-to-severe headache (mean difference, 2.59; 95% CI, 0.91 to 4.27; p=0.003.

Yang (2016) identified the same five RCTs as Chen.[3] The Yang review only included studies conducted with patients with migraine of at least six months in duration who did not respond to oral medications. In addition to the RCTs, five case series met the inclusion criteria. Yang et al did not pool study findings. The definition of response rate varied across studies and could include frequency and/or severity of headaches. Response rates in three case series with self-reported efficacy were 100% each, and response rates in the other two series were 50% and
89%, respectively. Complication rates in the series ranged from 40% to 100%. The authors noted that the case series were subject to biases (e.g., inability to control for the placebo effect), that RCT evidence was limited, and that complication rates were high.

Sweet (2015) published a SR that identified nine small case series (<15 patients each) assessing the efficacy of ONS for treating medically refractory occipital neuralgia. The authors did not pool study findings. No conclusions can be drawn about the impact of ONS on occipital neuralgia due to the lack of RCTs or other controlled studies.

The National Institute for Health and Care Excellence (NICE, 2013) evaluated two RCTs and one case series to determine if ONS was effective in decreasing headache frequency, duration and severity. Both RCTs compared ONS with sham stimulation at three months. Although the smaller RCT with 67 patients determined that the ONS group responded better than the sham group, the larger RCT with 157 patients showed no difference in responder rate. NICE concluded that ONS for intractable chronic migraines is efficacious in the short-term, but there is little evidence to indicate long-term outcome effects. NICE stated ONS should only be used for clinical governance, consent, and audit or research.

**RANDOMIZED CONTROLLED TRIALS**

Serra and Marchioretto (2012) conducted a crossover RCT in which 30 patients with chronic migraine (100% of patients) and medication overuse headache (85% of patients) were implanted with an ONS and randomized to “Stimulation On” or “Stimulation Off” arms. After one month, or if headaches worsened during the off period, patients were crossed over to the other arm. The mean number of days when patients randomized to the off condition turned on the generators was 4.65 days (range, 1-12 days). Follow-up examinations were conducted at one, three, six, and 12 months after nerve stimulator implantation, during which time the stimulation parameters were adjusted in order to optimize the perception of paresthesia. In addition, the patients were provided with remote controls to modify the stimulation amplitude. At baseline, the average frequency of migraines was 5.8 days per week and the median headache severity was eight on an 11-point numerical rating scale. Headache intensity and/or frequency were significantly lower in the on arm compared to the off arm and decreased from baseline to each follow-up visit in all patients with Stimulation On. For example, the number of headaches decreased from a median of 6.3 days per week in the off phase to 2.1 days per week in the on phase. The median Migraine Disability Assessment (MIDAS) score decreased from 79 at baseline to 10 at 12-month follow-up. Quality of life measured by the SF-36 significantly improved from baseline throughout the follow-up period. Use of triptans decreased from a median of 20 to three doses/month and use of nonsteroidal anti-inflammatory drug (NSAIDs) use decreased from a median of 25.5 to two doses/month. There were two infections (6.7%) and three lead migrations (10%) during the study. This study is limited by the lack of a control group during follow-up and lack of blinding, although blinding of patients may be difficult due to paresthesia with this treatment.

Silberstein (2012) published an RCT of patients diagnosed with chronic migraine (CM), implanted with a neurostimulation device and randomized 2:1 to active (n=105) or sham (n=52) stimulation. Authors defined the primary endpoint as the difference in the percentage of responders (defined as patients that achieved a ≥50% reduction in mean daily visual analog scale scores) in each group at 12 weeks. A significant difference was reported at a secondary endpoint of 30% reduction; however, no difference was reported between groups at the primary endpoint of 50% reduction. At a 30% reduction, significant difference in reduction of
number of headaches, migraine-related disability, and direct reports of pain relief were reported compared to the sham group, but it is unknown if these results are clinically meaningful considering researchers did not meet their established primary endpoint of at least a 50% reduction in mean daily analog scores. In addition, the overall treatment effect was low, with only 17.1% of the active group and 13.5% of the control group classified as responders.

Results from the 52-week open-label extension of this study were published in 2014.[8] Results were reported for the intent-to-treat (ITT) population and for the 125 patients who met criteria for intractable chronic migraine. Twenty-four patients were excluded from analysis due to explantation of the system (n=18) or other loss to follow-up. Mean headache days at baseline were 21.6 for the ITT population and 24.2 for the intractable chronic migraine group. In the ITT population, headache days were reduced by 6.7 days, and a 50% or greater reduction in headache days and/or pain intensity was observed in 47.8% of patients. Sixty-eight percent of patients were satisfied with the headache relief provided by the device. Seventy percent experienced at least one of 183 device-related adverse events, of which 8.6% required hospitalization and 40.7% required surgical intervention. Eighteen percent of patients had persistent pain and/or numbness with the device.

A small industry-sponsored feasibility RCT reported preliminary safety and efficacy data on occipital nerve stimulation (ONS) for treatment of medically intractable chronic migraine (CM).[9] However, the findings from this small (n=110) and very short (follow-up=three months) study must be interpreted with caution due to the exploratory nature of the design:

- The sample size was chosen to gain experience with ONS and the study was not prospectively powered for efficacy evaluation.
- No primary end points were specified at the outset; at three months, a range of efficacy measures were evaluated in comparison to baseline.

Although the findings from this study may provide direction for future research, they do not provide reliable evidence on the clinical utility of ONS. Per the authors, “reliable conclusions regarding efficacy cannot be established on the basis of this study alone.”

NONRANDOMIZED STUDIES

Evidence from nonrandomized studies of occipital nerve stimulation (ONS) for treatment of headaches is considered insufficient due to methodological limitation such as nonrandom allocation of treatment, lack of adequate comparison groups, small sample size, and short-term follow-up, all of which limit conclusions regarding the safety and effectiveness of ONS treatment.[10] Of note, several of these nonrandomized studies reported high rates of ONS revision (20-60%)[11-13] and/or complications (20-40%)[10,12,14].

PRACTICE GUIDELINE SUMMARY

CONGRESS OF NEUROLOGICAL SURGEONS

A 2015 evidence-based guideline from the Congress of Neurological Surgeons states: “the use of occipital nerve stimulation is a treatment option for patients with medically refractory occipital neuralgia.”[4] The statement had a level III recommendation based on a SR of the literature that only included case series with methodological limitations.

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
A 2013 National Institute for Health and Care Excellence (NICE) guideline noted that the evidence on ONS for intractable chronic migraine shows some efficacy for short-term outcomes but very little evidence about long-term outcomes. With regard to safety, NICE indicated that there are risks of complications that may need further surgery. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. NICE has recommended that clinicians wanting to undertake ONS for intractable chronic migraine should ensure that patients understand the uncertainty about the procedure’s safety and efficacy, and provide them with clear written information.

**SUMMARY**

There is not enough research to show that occipital nerve stimulation (ONS) improves health outcomes for patients with any condition. Clinical guidelines based on research list ONS as a treatment option, but highlight the uncertainty around safety and health outcomes. Therefore, ONS is considered investigational for all indications, including but not limited to as a treatment of headache.

**REFERENCES**


<table>
<thead>
<tr>
<th>Codes</th>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>0466T</td>
<td>Insertion of chest wall respiratory sensor electrode or electrode array, including connection to pulse generator (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td></td>
<td>61885</td>
<td>Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to a single electrode array</td>
</tr>
<tr>
<td></td>
<td>61886</td>
<td>Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to 2 or more electrode arrays</td>
</tr>
<tr>
<td></td>
<td>64553</td>
<td>Percutaneous implantation of neurostimulator electrode array; cranial nerve</td>
</tr>
<tr>
<td></td>
<td>64555</td>
<td>Percutaneous implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve)</td>
</tr>
<tr>
<td></td>
<td>64568</td>
<td>Incision for implantation of cranial nerve (e.g., vagus nerve) neurostimulator electrode array and pulse generator</td>
</tr>
<tr>
<td></td>
<td>64569</td>
<td>Revision or replacement of cranial nerve (e.g., vagus nerve) neurostimulator electrode array, including connection to existing pulse generator</td>
</tr>
<tr>
<td></td>
<td>64570</td>
<td>Removal of cranial nerve (e.g., vagus nerve) neurostimulator electrode array and pulse generator</td>
</tr>
<tr>
<td></td>
<td>64575</td>
<td>Incision for implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve)</td>
</tr>
<tr>
<td></td>
<td>64585</td>
<td>Revision or removal of peripheral neurostimulator electrode array</td>
</tr>
<tr>
<td></td>
<td>64590</td>
<td>Insertion or replacement of peripheral or gastric neurostimulator pulse generator or receiver, direct or inductive coupling</td>
</tr>
<tr>
<td></td>
<td>64999</td>
<td>Unlisted procedure, nervous system</td>
</tr>
<tr>
<td></td>
<td>95970</td>
<td>Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulsewidth, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional;</td>
</tr>
<tr>
<td>Codes</td>
<td>Number</td>
<td>Description</td>
</tr>
<tr>
<td>-------</td>
<td>--------</td>
<td>-------------</td>
</tr>
<tr>
<td></td>
<td>95971</td>
<td>with simple spinal cord, or peripheral nerve (eg, sacral nerve) neurostimulator pulse generator/transmitter, without programming</td>
</tr>
<tr>
<td></td>
<td>95972</td>
<td>with complex spinal cord, or peripheral nerve (eg, sacral nerve) neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional</td>
</tr>
<tr>
<td>HCPCS</td>
<td>C1820</td>
<td>Generator, neurostimulator (implantable), with rechargeable battery and charging system</td>
</tr>
<tr>
<td></td>
<td>L8679</td>
<td>Implantable neurostimulator, pulse generator, any type</td>
</tr>
<tr>
<td></td>
<td>L8680</td>
<td>Implantable neurostimulator electrode, each</td>
</tr>
<tr>
<td></td>
<td>L8681</td>
<td>Patient programmer (external) for use with implantable programmable neurostimulator pulse generator, replacement only</td>
</tr>
<tr>
<td></td>
<td>L8682</td>
<td>Implantable neurostimulator radiofrequency receiver</td>
</tr>
<tr>
<td></td>
<td>L8683</td>
<td>Radiofrequency transmitter (external) for use with implantable neurostimulator radiofrequency receiver</td>
</tr>
<tr>
<td></td>
<td>L8685</td>
<td>Implantable neurostimulator pulse generator, single array, rechargeable, includes extension</td>
</tr>
<tr>
<td></td>
<td>L8686</td>
<td>Implantable neurostimulator pulse generator, single array, non-rechargeable, includes extension</td>
</tr>
<tr>
<td></td>
<td>L8687</td>
<td>Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension</td>
</tr>
<tr>
<td></td>
<td>L8688</td>
<td>Implantable neurostimulator pulse generator, dual array, non-rechargeable, includes extension</td>
</tr>
<tr>
<td></td>
<td>L8689</td>
<td>External recharging system for battery (internal) for use with implantable neurostimulator</td>
</tr>
</tbody>
</table>

*Date of Origin: June 2010*